Drugs / [177Lu]Lu-DOTA-TATE
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06379217 | Jul 2024 → Aug 2026 overdue | prostate neuroendocrine neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05109728 | May 2022 → Dec 2025 overdue | glioblastoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05142696 | Jul 2022 → Mar 2028 expected | small cell lung carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06955169 | Dec 2025 → Aug 2029 | intracranial meningioma | RTOG Foundation, Inc. | Suspended | No outcome recorded |
| Phase 2 | NCT03454763 | May 2016 → Jan 2025 overdue | neuroendocrine neoplasm | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [177Lu]Lu-DOTA-TATE | “Following NETTER-1 trial, PRRT with [177Lu]Lu-DOTATATE was approved by FDA and EMA and is routinely employed in advanced G1 and G2 SST (somatostatin receptor)-expressing NET.” PMID 38581469 ↗ Apr 2024 |
| Known as | 177lu-dotatate | “Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors” NCT03454763 ↗ |
| Modality | Other / unclassified | “targeted radioligand therapy (RLT)” NCT06379217 ↗ |
| Route | Intravenous | “intravenous infusion” NCT06379217 ↗ |